Circulating MicroRNAs in Understanding Pathogenesis of Systemic Lupus Erythematosis

Cairo University100 enrolled

Overview

This study aims to identify the expression signature of miR-181a, miR-196a and miR-21 in plasma of SLE patients and difference in their expression among groups with different systemic lupus erythematosis disease activity index (SLEDAI) scores.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

100

Conditions

Systemic Lupus Erythematosis

Interventions

CyclophosphamideDRUG

HydroxychloroquineDRUG

HydrocortisoneDRUG

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Adult systemic lupus erythematosis patients Exclusion Criteria: * Patients younger than 18 years, patients with other autoimmune diseases or malignancy.

Outcomes

Primary Outcomes

MicroRNAs expression level

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.